Related Experiment Videos
Cost-effectiveness of prenatal testing for Chlamydia trachomatis.
1Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.
American Journal of Obstetrics and Gynecology
|May 1, 1991
Summary
Screening pregnant women for Chlamydia trachomatis is not always cost-effective. Direct antigen testing may be economical under specific cost and prevalence conditions, with modest excess costs overall.
Area of Science:
- Public Health
- Infectious Disease Prevention
- Health Economics
Background:
- Chlamydia trachomatis is a common sexually transmitted infection.
- Screening pregnant women for Chlamydia trachomatis is recommended to prevent complications.
- The cost-effectiveness of different screening strategies requires evaluation.
Purpose of the Study:
- To assess the cost-effectiveness of various screening strategies for Chlamydia trachomatis in pregnant women.
- To determine the conditions under which screening becomes economically viable.
Main Methods:
- Cost-effectiveness analysis of different Chlamydia trachomatis screening strategies.
- Modeling scenarios based on varying test costs and infection prevalence.
- Evaluation of direct antigen testing and culture methods.
Main Results:
- Chlamydia trachomatis screening is not cost-effective unless specific conditions are met.
- Direct antigen testing is cost-effective if test cost < $6.30 or prevalence > 6%.
- Culture-based screening is cost-effective only if prevalence exceeds 14.8%.
Conclusions:
- The cost-effectiveness of Chlamydia trachomatis screening in pregnant women is highly dependent on test costs and infection prevalence.
- Direct antigen testing offers a potentially more cost-effective approach compared to culture under certain thresholds.
- While not universally cost-effective, the incremental cost of using direct antigen tests is relatively small.